Introduction
============

Porcine reproductive and respiratory syndrome (PRRS) was first described in 1987 in United States and subsequently discovered in 1990 in Europe. Despite ofchronicle proximity of the discovery, presumably derived from common ancestor and structural similarity of the viruses, these isolates from two different continents showed very distinct genotypes. The PRRS virus (PRRSV) has spread worldwide and became a most economically important disease in swine industry. PRRSV is a single-stranded, positive-sense RNA virus belongs to family *Arteriviridae* of the order of *Nidovirales*. The virus has genome of \~15 kb which encode around 10 open reading frames, ORF1a, ORF1b, ORF2a, ORF2b, ORF3, ORF4, ORF5, ORF6, and ORF7. Viral protease process translated polyproteins of ORF1a and ORF1b into 14 different non-structural proteins (NSPs). These NSPs have been identified to have function in viral replication and transcription machinery, and some of them involved in regulation of the viral pathogenesis through their involvement in host innate immune response modulation \[[@B1]\].

The major clinical features of the disease are late term reproductive failure in pregnant sows and respiratory problems in piglets and growing pigs resulting in enormous economic loses. A tremendous effort has been made to protect pigs from this economically devastating disease by developing such as killed, modified live, recombinant protein based, and DNA vaccines \[[@B2][@B3][@B4][@B5][@B6]\]. But, only cell culture attenuated virus vaccine is practiced in the field with arguably limited efficacy. The PRRSV vaccine did not clear virus from infected pigs nor prevent re-infection of the virus ([Fig. 1](#F1){ref-type="fig"}) \[[@B7]\]. The vaccine showed no adequate innate immune reaction, low anamnestic immune response and negligible cell mediated immunity \[[@B8]\]. Despite of the current developed scientific technology, there still remain many questions to solve a most important pig disease worldwide. Therefore, no vaccines providing solid protective immunity with excellent safety for the PRRSV have been developed yet.

Infectious diseases in modern animal production exert an enormous economic burden in the industry, instability of the meat market, animal welfare and may threaten human health depending on the infectious agents.To protect animals from infectious disease, vaccinology is considered a most effective solution in animal health. Series of good animals vaccines such as modified live vaccine (MLV) of classical swine fever and canine distemper known to be very effective in vaccinated animals to protect respective virus infection after proper vaccination. Influenza vaccines in animals and human have difficulties to formulate precise antigen make up to expect seasonal epidemics of the serotype and/or subtypes within the serotypes. Genetic heterogeneity of the field virus dampens efficacy of the vaccine and protection of the disease in vaccinated herd but still antigens in the vaccine formulation elicit good immune response.

Despite the current scientific achievement in immunology and vaccinology, vaccines against human immunodeficiency virus (HIV) in human and African swine fever in pigs are not available at the moment. Efficacy of the animal vaccines currently available varies depending on immunogens in vaccine formula such as modified live, killed or recombinant proteins.

PPRSV persist long term in the infected host due to the delayed and lack of both innate and adaptive immunity. As well huge discrepancies were observed between experimentally infected groups in isolated facilities and observations made in the farm animals.

Innate Immunity
===============

The early stage of a virus infection in animals is a critical race between the infected virus and host\'s immune system, in which host try to halt virus replication and defend invaders. There are various physico-chemical barriers to defend against virus infection such as acidic pH, proteolytic enzymes, and layers of mucus. The innate immune system plays very important role in control of the early stage of virus replication and delay spread of the virus to other parts of the body. Especially, the innate immunity differs from specific immunity, which elicit broad-spectrum of the anti-viral effect. Innate immunity is triggered by recognition of the microbial patterns characteristic of virus but not host cellular components. Type I interferons (IFNs) exert direct anti-viral activity as well activate other innate and adaptive immune responses. Measuring type I IFN response in virus infected animals is often used as a reliable good tool to evaluate innate immunity of the host. The type I IFN is a major player of the host innate immune response in viral infection. During a virus infection and replication process, viral intermediates trigger the expression of the IFN gene in cells and infected host. In this events, the RIG-1 like helicase and TLR-3 trigger signaling cascade and activate IRF3, nuclear factor kB and ATF-2 that drives IFN gene expression. Nsp1 (nsp1 subunits) of the PRRSV partly blocks type I IFN production in the virus infected cells \[[@B1][@B9]\]. The PRRSV infected host either does not produce IFN or showed significantly reduced production of the IFN, which is an important host defense mechanism in virus infected cells that eventually provide virus spread to the adjacent cells. Not only nsp1 but other PRRSV nsp are also modulate innate immune signaling pathways ([Table 1](#T1){ref-type="table"}).

Humoral Immunity
================

Specific antibodies to the antigen provide major barrier against virus spread between susceptible cells and tissues are particularly important in limiting virus spread through vascular system. Classical immunology claims that neutralizing antibody is the first line of the defense against free virus particles. Virus neutralization test provides an important indicator for the humoral protection index in virus-infected host. PRRSV is different other common virus infection. Pigs either infected or vaccinated pigs respond to the PRRSV proteins and produce virus specific antibodies but early antibodies did not show virus-neutralizing activities \[[@B10]\]. As shown in [Fig. 2](#F2){ref-type="fig"}, viremia last long time in the infected pigs and gradually diminished and total antibody response was similar to that of the other viral infection but appearance of the serum neutralizing antibody was independent to viral clearance ([Fig. 2](#F2){ref-type="fig"}) \[[@B11]\]. This indicates that virus clearance is not directly responsible for the protection even neutralization antibody is an important factor for the humoral protection mechanism. Research data obtained in late 90s thought PRRSV is persistent in the infected animals, which is reliable reason that memory responses would be difficult to demonstrate *in vivo* due to the continual presence of antigen that could simply be eliciting active immunity \[[@B12]\]. During the course of acute with prolonged viremia, lymphoid tissue infection, PRRSV-specific memory B-cells peak in number at 40-100 days of infection then declined \[[@B13]\]. But, re-challenge with genetically similar or unrelated viruses at about 200 days of infection did not show any noticeable anemnestic response (Murtaugh, unpublished data). Rather, the parameters of infection and host immunity need to be determined and immunological effector responses evaluated for usefulness as surrogate measures of protection against future infectious challenge. Another key feature of the adaptive immunity are the establishment of the immunological memory, which is very common in animals vaccinated and/or naturally infected. However, the PRRSV vaccinated and/or infected pigs did not show booster effect by the second exposures of the antigen \[[@B14]\]. Measuring total antibodies by an enzyme-linked immunosorbent assay or neutralization antibodies by virus neutralization test did not provide similar result that of other animal vaccines ([Fig. 1](#F1){ref-type="fig"}). The research finding from the previous study that antibody avidity correlates with virus clearance from the circulating blood indicates that maturation of the antibody plays an important role in free virus control in the virus infected host animals. Groups of pigs with high avidity to PRRSV showed low mortality and low avidity groups showed relatively higher mortality ([Figs. 1](#F1){ref-type="fig"}, [3](#F3){ref-type="fig"}).

Cell Mediated Immunity
======================

T cells exhibit multiple functions in antiviral immunity such as restricting establishment of virus infections, immunoglobulin isotype switching and maturation, activation of macrophages and protecting re-infections of the virus to other tissues.

To promote virus survival in the infected host, viruses have evolved various strategies for evasion from the host immune system. Evasion strategies of the virus can be categorized according to mechanisms such as impairing host response, avoiding recognition by the host immune system and restricting control by immune effector mechanism. In the course of the either European or North American type virus infection showed very little if any PRRSV-specific IFN-γ releases response from whole blood, whereas non-specific responses were consistently observed \[[@B15][@B16][@B17]\]. As shown in [Fig. 2](#F2){ref-type="fig"} viral clearance in the blood and viral load in the lymphoid tissue does not co-relate with cell-mediated immunity. IFN-γ assay is neither absolute nor only indicator for the evaluation of the cell-mediated immunity but this assay is common method for the cell-mediated immune (CMI) response. Highly variable number of the T cell in either acutely or persistently animals were detected and showed no close correlation to the level of the virus in the lymphoid tissues. There are no significant changes in CD4+ and CD8+ T-cell frequencies after PRRSV infection were observed, though a decrease number of gamma and delta T cells were recorded \[[@B18]\]. This result support that there is no or very little contribution of the CMI to the PRRSV infection and suggest PRRSV suppresses T-cell recognition of the infected macrophages. Even weak CMI response in PRRSV infection, 9 antigenic regions on the 5 of the viral proteins determined by IFN-γ ELISpot assay indicate that there are T-cell specific epitopes on the viral proteins \[[@B19]\].

Conclusion
==========

Despite the current scientific achievement in immunology and vaccinology, vaccines against HIV in human and African swine fever in pigs are not available at the moment. Efficacy of the animal vaccines currently available varies depending on immunogens in vaccine formula such as modified live, killed or recombinant proteins. To protect animals from infectious diseases, vaccination has been considered a most effective solution in animal health. Series of good animal vaccines has been developed and practiced such as MLV of classical swine fever and canine distemper. These vaccines are known to be very effective in protection against the respective disease agents for the properly vaccinated animals. Despite the good success of various types of vaccines, influenza vaccines in animals and human have been experienced difficulties in formulating precise antigen make-up through expecting in-coming seasonal epidemics of the serotype and/or subtypes within the serotypes. Often genetic heterogeneity of the field virus dampens efficacy of the vaccine and protection of the disease in vaccinated herd but still antigens in the vaccine formulation elicit good immune response. Several viral agents efficiently evade host immune system and survive prolonged time in the host tissues.

Infectious diseases in modern animal production exert an enormous economic burden in the industry, instability of the meat market, animal welfare and may threaten human health depending on the infectious agents.

PPRSV persist long term in the infected host due to the delayed and lack of both innate and adaptive immunity. As well huge discrepancies were observed between experimentally infected groups in isolated facilities and observations made in the farm animals \[[@B20]\]. Viruses evolved and earned various evasion strategies to host immune system. PRRSV have at least several evasion tools to survive prolonged time in the infected host \[[@B21][@B22]\]. Non-structural proteins of the PRRSV plays very important role to inhibit innate immunity and several mechanisms were investigated. Since there is no close correlation between viral clearance and neutralization antibody, we need to find a mechanism behind viral elimination from the blood and tissues. Viruses evolved and earned various evasion strategies to host immune system. PRRSV have at least several evasion tools to survive prolonged time in the infected host based on the known fact such as poor innate immunity, low anamnestic humoral immune response and negligible cellular immunity in early infection. PPRSV persist long term in the infected host due to the delayed and lack of both innate and adaptive immunity. As well huge discrepancies were observed between experimentally infected groups in isolated facilities and observations made in the farm animals. Current understandings on the PRRSV vaccinology is a tip of icebergs and further studies to develop measures against PRRSV infection in the pigs are seemed to be needed.
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![Relationship between pig mortality and antibody avidity to porcine reproductive and respiratory syndrome virus (PRRSV) was investigated in pig farms. Mortality of over 15%, 10%-15%, 5%-10%, and less than 5% were grouped and avidity of the antibody to PRRSV was determined. Reproduced from Seo and Sunwoo (2012), Proceeding of the 22nd International Pig Veterinary Society Congress \[[@B7]\].](cevr-4-159-g001){#F1}

![The porcine reproductive and respiratory syndrome virus (PRRSV) infection and repertoire of the immune response in the virus infected pigs. Reproduced from Lopez and Osorio (2004), Elsevier, Veterinary Immunology and Immunopathology \[[@B11]\]. ELISA, enzyme-linked immunosorbent assay; IFN-γ, interferon γ.](cevr-4-159-g002){#F2}

![Antibody maturation leads virus clearance in the vaccinated pigs after challenge. Pigs were vaccinated and virus in the blood and avidity of the antibody specific to porcine reproductive and respiratory syndrome virus (PRRSV) was monitored. Reproduced from Seo and Sunwoo (2012), Proceeding of the 22nd International Pig Veterinary Society Congress \[[@B7]\].](cevr-4-159-g003){#F3}
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Arterivirus proteins modulating innate immune signaling

![](cevr-4-159-i001)

  Virus                                                                  Protein                                                                Modulatory function for innate immunity
  ---------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------
  PRRSV                                                                  nsp1*a*                                                                Inhibits production of type I IFNs and impairs IFN promoter activity
  Suppresses NF-κB activation                                                                                                                   
  Induces CBP degradation                                                                                                                       
  Suppresses TNF-α promoter activity                                                                                                            
  nsp1*13*                                                               Inhibits production of type I IFNs and impairs IFN promoter activity   
  Impairs IRF3 phosphorylation and IRF3 nuclear localization                                                                                    
  Interferes with IFN-α induction and ISG expression                                                                                            
  nsp2 (PLP2)                                                            Blocks nuclear translocation of ISGF3 by inducing KPNA1 degradation    
  Suppresses TNF-α promoter activity                                                                                                            
  Antagonizes type I interferon induction                                                                                                       
  Interferes with NF-κB signaling pathway                                                                                                       
  Prevents IκBα degradation by OTU domain                                                                                                       
  Inhibits ISG15 production and ISGylation                                                                                                      
  Activates NF-κB                                                                                                                               
  nsp4                                                                   Inhibits IFN-13 promoter activity                                      
  Suppresses NF-κB mediated signaling pathway in the nucleus                                                                                    
  nsp11                                                                  Impair IFN promoter activity                                           
  Participates in suppression of RIG-I signaling                                                                                                
  Degrades mRNA of IPS-1                                                                                                                        
  Inhibits production of type I IFNs and impairs IFN promoter activity                                                                          
  N                                                                      Impairs IRF3 phosphorylation and IRF3 nuclear localization             
  Upregulates IL-10 gene expression                                                                                                             
  Activates NF-κB                                                                                                                               
  EAV                                                                    nsp1                                                                   Inhibits production of type I IFNs and impairs IFN promoter activity
  nsp2 (PLP2)                                                            Inhibits RIG-I-mediated innate immune signaling                        
  Inhibits RIG-I ubiquitination by its DUB activity                                                                                             
  LDV                                                                    nsp1*a*                                                                Inhibits production of type I IFNs and impairs IFN promoter activity
  Induces CBP degradation                                                                                                                       
  nsp1*13*                                                               Inhibits production of type I IFNs and impairs IFN promoter activity   
  SHFV                                                                   nsp1*a13*                                                              Inhibits production of type I IFNs and impairs IFN promoter activity

Han and Yoo. Virus Res 2014;194:100-9 \[[@B1]\].

PRRSV, porcine reproductive and respiratory syndrome virus; nsp, nonstructural protein; IFN, interferon; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; CBP, CREB-binding protein; TNF, tumor necrosis factor; IRF, interferon regulatory transcription factor; ISG, interferon-stimulated gene; PLP, papain-like cysteine protease; ISGF, interferon-stimulated gene factor; KPNA, karyopherin alpha 1; IκBα, NF-κB1; OTU, ovarian tumor; IL, interleukin.
